Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy

Journal of Virology

Volumn 76, Issue 5, 2002, Pages 2206-2216

  Jin, Xia ^a   Ramanathan Jr , Murugappan ^a   Barsoum, Shady ^a   Deschenes, Geoffrey R ^a   Ba, Lei ^a   Binley, James ^a   Schiller, Daryl ^a   Bauer, Daniel E ^a   Chen, Donald C ^a   Hurley, Arlene ^a   Gebuhrer, Lucette ^a   El Habib, Raphaelle ^a   Caudrelier, Pierre ^a   Klein, Michel ^a   Zhang, Linqi ^a   Ho, David D ^a   Markowitz, Martin ^a  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALVAC VCP1452 PLUS RECOMBINANT GLYCOPROTEIN GP 120; AMPRENAVIR; ANTIGEN P24; ANTIRETROVIRUS AGENT; CD8 ANTIGEN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IBUPROFEN; INDINAVIR; LAMIVUDINE; PARACETAMOL; RECOMBINANT PROTEIN; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG; VIRUS VECTOR; ZIDOVUDINE;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; DRUG SAFETY; FEVER; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION PAIN; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; SYMPTOM; T LYMPHOCYTE; VACCINATION; VIREMIA; VIRUS RECOMBINANT; VIRUS TITRATION;

AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; MALE; RECOMBINATION, GENETIC; RNA, VIRAL; T-LYMPHOCYTES; VACCINATION; VACCINES, COMBINED; VIRAL VACCINES;

EID: 0036168676     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.76.5.2206-2216.2002     Document Type: Article

References (61)

1. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120
2. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
3. Phenotypic analysis of antigen-specific T lymphocytes
4. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1
5. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
6. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
7. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults
8. The Th1-Th2 hypothesis of HIV infection: New insights
9. Glimmerings of hope from the bottom of the well
10. Oligonucleotide genotyping of HLA polymorphism on microtitre plates
11. HIV-1 and T-cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
12. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
13. Efficient human immunodeficiency virus (HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate
14. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
15. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
16. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160
17. Effects of the Th1 and Th2 stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication
18. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells
19. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
20. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
21. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
22. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques
23. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
24. Dramatic rise in plasma viremia after CD8+ T-cell depletion in SIV-infected macaques
25. An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes
26. Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: In vitro quantitation of effector cell populations with p17 and p24 specificities
27. Temporal association of cellular immune response with the initial control of viremia in primary HIV-1 syndrome
28. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine
29. Control of SIV rebound through structured treatment interruptions during early infection
30. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
31. A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection
32. HIV-1 coreceptors, neutralization serotypes and vaccine development
33. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120 and their neutralization is not predicted by studies with monomeric gp120
34. Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen
35. Human trials of HIV-1 vaccines
36. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinltiated treatment
37. Quantitation of HIV-1specific cytotoxic T lymphocytes and plasma load of viral RNA
38. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation
39. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
40. The safety and use of canarypox vectored vaccines
41. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
42. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research
43. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
44. Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men
45. Role of TH1/TH2 cytokines in HIV infection
46. Immune control of HIV-1 after early treatment of acute infection
47. Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viremia
48. Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV type 1 infection
49. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
50. Enhanced immunogenicity for CD8+ T-cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus virus Ankara
51. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214
52. Boosting with recombinant vaccinia virus increases immunogenicity and protective efficacy of malaria DNA vaccine
53. Highly attenuated poxvirus vectors
54. NYVAC: A highly attenuated strain of vaccinia virus virus
55. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65), in nonavian species
56. Nonreplicating viral vectors as potential vaccines: Recombinant canarypox expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins
57. 3 CD4 T lymphocytes
58. Viral dynamics in human immunodeficiency virus type 1 infection
59. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
60. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers
61. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy